BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

NCT01169675 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: BIBW 2992 low dose
DRUG: BIBW 2992 high dose
DRUG: pemetrexed
DRUG: pemetrexed
DRUG: BIBW 2992 high dose 6 day
DRUG: pemetrexed
DRUG: pemetrexed
DRUG: pemetrexed
DRUG: pemetrexed
DRUG: BIBW 2992 low dose 6 day
DRUG: BIBW 2992 medium dose 6 day
DRUG: BIBW 2992 medium dose

Sponsor

Boehringer Ingelheim